Jia-Hui Huang, Shu-Huey Chen, Yu-Mei Liao, Yu-Chien Kao, Wan-Ling Ho, Hsi Chang, Min-Lan Tsai, Hsin-Lun Lee, Chia-Chun Kuo, Sung-Hui Tseng, Chia-Yau Chang, Kevin Li-Chun Hsieh, Long-Sheng Lu, Yin-Ju Chen, Jeng-Fong Chiou, Tsung-Han Hsieh, Yun-Ru Liu, Wayne Hsu, Wei-Tang Li, Yu-Chung Wu, Wei-Ciao Wu, Jinn-Li Wang, Jia-Jia Tsai, Keita Terashima, Chikako Kiyotani, Tai-Tong Wong, James S Miser, Yen-Lin Liu
Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2 ), doxorubicin (75 mg/m2 ), and cyclophosphamide (1200-2200 mg/m2 ) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2 ) and etoposide (500 mg/m2 ) (IE), with filgrastim (5-10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2 ) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15-24 days...
April 14, 2023: Journal of Personalized Medicine